Arif Ajmeri
Family Medicine · Oklahoma City, OKNPI 1710322268
Payments from drug & device makers
Across 83 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$207
- Amgen$185
- GSK$160
- Merck$153
- Pfizer$137
- AbbVie$70
- plus $443 from 14 others
What the payments were for
- Food & beverage$1,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $207 |
| Amgen | 11 | $185 |
| GSK | 9 | $160 |
| Merck | 12 | $153 |
| Pfizer | 8 | $137 |
| AbbVie(2 entities) | 4 | $70 |
| Novo Nordisk | 5 | $64 |
| Bayer | 2 | $62 |
| Exact Sciences | 3 | $54 |
| Lilly USA, LLC | 2 | $38 |
| Boehringer Ingelheim | 2 | $37 |
| Abbott | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Scilex Pharmaceuticals Inc. | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $20 |
| AstraZeneca | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Insulet Corporation | 1 | $14 |
| Organon | 1 | $10 |
How this compares
$1,355 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 95 | $130,220 |
| JanuviaSitagliptin Phosphate | 79 | $87,369 |
| JardianceEmpagliflozin | 64 | $86,368 |
| EliquisApixaban | 58 | $73,356 |
| OzempicSemaglutide | 40 | $44,593 |
| TrulicityDulaglutide | 21 | $26,482 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $4,846 |
| Omeprazole | 220 | $3,687 |
| Arnuity ElliptaFluticasone Furoate | 14 | $2,753 |
| Levothyroxine Sodium | 290 | $2,737 |
| Atorvastatin Calcium | 268 | $2,541 |
| Montelukast Sodium | 132 | $2,415 |
| Ventolin HfaAlbuterol Sulfate | 23 | $2,250 |
| Simvastatin | 75 | $2,098 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $2,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $38 | $156,702116 claims |
| MerckJanuvia | $153 | $87,36979 claims |
| Boehringer IngelheimJardiance | $37 | $86,36864 claims |
| PfizerEliquis | $137 | $73,35658 claims |
| Novo NordiskOzempic | $64 | $44,59340 claims |
| GSKArnuity Ellipta | $160 | $2,75314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Charles LunnOklahoma City$1.4M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.